• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

One-Third of COVID-19 Survivors May Develop a Neuropsychiatric Disorder Within Months of Infection
One-third of individuals diagnosed with COVID-19 developed a psychiatric or neurological problem within six months of their diagnosis, according to astudy published Tuesday inThe Lancet Psychiatry. The prevalence of a post-COVID neurologic or psychiatric diagnosis was even greater among individuals with severe illness who had required hospitalization.“Given the size of the pandemic and the chronicity of many of the diagnoses and their consequences (for example, dementia, stroke, and intracranial hemorrhage), substantial effects on health and social care systems are likely to occur,” wrote Maxime Taque, Ph.D., of the Un...
Source: Psychiatr News - April 7, 2021 Category: Psychiatry Tags: anxiety COVID-19 electronic health records hospitalizations mood disorders neuropsychiatric disorders The Lancet Psychiatry Source Type: research

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Neurological Effects of Monkeypox Largely Unknown, Review Finds
Much remains unknown about the long-term neurologic effects of monkeypox. In anarticle published today inJAMA Neurology, researchers from the National Institute of Neurological Disorders and Stroke (NINDS) and colleagues described how reports of complications from other orthopoxviruses, such as smallpox, may offer clues about the neurologic consequences of monkeypox.“Although the COVID-19 pandemic is the worst pandemic in a century, the recent past has seen several major pandemics, including Zika, Ebola, dengue, West Nile, and AIDS,” wrote B. Jeanne Billioux, M.D., of NINDS and colleagues. “A common thread to these p...
Source: Psychiatr News - September 20, 2022 Category: Psychiatry Tags: febrile seizures/encephalopathy headache JAMA Neurology monkeypox neurological problems smallpox transverse myelitis Source Type: research

U.S. FDA Approves TECVAYLI ™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., October 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved TECVAYLI™ (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma, who previously received four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.1 TECVAYLI™ is a first-in-class, bispecific T-cell engager antibody that is administered as a subcutaneous treatment.1 This off-the-shelf (or ready to use) therapy uses innovative science to ac...
Source: Johnson and Johnson - October 25, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news